CN117323352A - 一种具有足细胞保护活性的冬虫夏草提取物及其制备方法和应用 - Google Patents
一种具有足细胞保护活性的冬虫夏草提取物及其制备方法和应用 Download PDFInfo
- Publication number
- CN117323352A CN117323352A CN202311356381.2A CN202311356381A CN117323352A CN 117323352 A CN117323352 A CN 117323352A CN 202311356381 A CN202311356381 A CN 202311356381A CN 117323352 A CN117323352 A CN 117323352A
- Authority
- CN
- China
- Prior art keywords
- extract
- cordyceps sinensis
- water
- ethanol
- podocyte
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 77
- 241001248610 Ophiocordyceps sinensis Species 0.000 title claims abstract description 74
- 210000000557 podocyte Anatomy 0.000 title claims abstract description 60
- 230000000694 effects Effects 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 149
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 38
- 239000002244 precipitate Substances 0.000 claims abstract description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 21
- 241000190633 Cordyceps Species 0.000 claims abstract description 13
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 9
- 238000001035 drying Methods 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 239000011347 resin Substances 0.000 claims abstract description 6
- 229920005989 resin Polymers 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 4
- 239000003463 adsorbent Substances 0.000 claims abstract description 3
- 235000019441 ethanol Nutrition 0.000 claims description 56
- 208000020832 chronic kidney disease Diseases 0.000 claims description 24
- 238000000605 extraction Methods 0.000 claims description 18
- 239000013049 sediment Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 230000001681 protective effect Effects 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 7
- 230000036541 health Effects 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- 230000002633 protecting effect Effects 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003480 eluent Substances 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract description 36
- 229960004679 doxorubicin Drugs 0.000 abstract description 15
- 230000006378 damage Effects 0.000 abstract description 11
- 208000027418 Wounds and injury Diseases 0.000 abstract description 6
- 208000014674 injury Diseases 0.000 abstract description 6
- 238000001556 precipitation Methods 0.000 abstract description 4
- 206010061481 Renal injury Diseases 0.000 abstract description 3
- 230000001684 chronic effect Effects 0.000 abstract description 3
- 208000037806 kidney injury Diseases 0.000 abstract description 3
- 239000000843 powder Substances 0.000 abstract description 3
- 238000013329 compounding Methods 0.000 abstract description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 abstract 1
- 238000005119 centrifugation Methods 0.000 abstract 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 239000002904 solvent Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 6
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 5
- 208000033679 diabetic kidney disease Diseases 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 4
- 206010018372 Glomerulonephritis membranous Diseases 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 4
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 4
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 4
- 210000000585 glomerular basement membrane Anatomy 0.000 description 4
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 4
- 231100000855 membranous nephropathy Toxicity 0.000 description 4
- 238000002137 ultrasound extraction Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 3
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 3
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 3
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 3
- 206010021263 IgA nephropathy Diseases 0.000 description 3
- 229930010555 Inosine Natural products 0.000 description 3
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 229960005305 adenosine Drugs 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 229940029575 guanosine Drugs 0.000 description 3
- 229960003786 inosine Drugs 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 229940113082 thymine Drugs 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000130660 Hepialidae Species 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- TYSMTUXFPYIWLA-UHFFFAOYSA-N butan-1-ol;dichloromethane Chemical compound ClCCl.CCCCO TYSMTUXFPYIWLA-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000009693 chronic damage Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000001120 cytoprotective effect Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 241000726094 Aristolochia Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- BBFQZRXNYIEMAW-UHFFFAOYSA-N aristolochic acid I Chemical compound C1=C([N+]([O-])=O)C2=C(C(O)=O)C=C3OCOC3=C2C2=C1C(OC)=CC=C2 BBFQZRXNYIEMAW-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000002035 hexane extract Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- -1 polysaccharide compounds Chemical class 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种具有足细胞保护活性的冬虫夏草提取物及其制备方法和应用。该冬虫夏草提取物的制备步骤为:1)冬虫夏草干燥粉末依次采用正己烷、乙酸乙酯和无水乙醇提取,药渣干燥后用水提取,得到水提液W1,水提液W1脱蛋白处理后浓缩,经分级醇沉离心得到醇沉物W1CC~W4CC及水提液W2。2)水提液W2用大孔吸附树脂纯化,以乙醇/水混合液梯度洗脱,收集水‑20%乙醇‑水洗脱液,浓缩干燥,得到提取物W5CC。3)将醇沉物W1CC与提取物W5CC复配,得到冬虫夏草提取物。本发明的冬虫夏草提取物具有降低阿霉素诱导的足细胞损伤药效,其活性成分明确,可作为肾病综合征等慢性肾损伤治疗药物,具有广阔的应用前景。
Description
技术领域
本发明属于医药技术领域,具体涉及一种具有足细胞保护活性的冬虫夏草提取物及其制备方法和应用。
背景技术
随着医学技术的进步,以及生活条件的改善,人们的平均寿命不断增长,但同时也面临越来越严峻的人口老龄化问题。肾脏是易受机体衰老发生结构和功能改变的重要器官,慢性肾脏病(CKD)的患病率随年龄而增加。普通人群CKD的患病率为10%~13%,但老年人CKD的患病率可以达到30%~50%,是影响老年人生活质量的重大慢性疾病。全球有约8%~16%的人口罹患不同程度的CKD,中国有约10.8%的人患有CKD,是危害人类尤其是老年人健康的严重疾病。预防性干预并通过治疗逐渐恢复肾脏功能,是解决慢性肾脏病危害人类身心健康的有效措施。
慢性肾脏疾病是由原发或继发性肾脏损伤导致的一类疾病综合症,糖尿病肾病(DN)、原发性肾小球肾炎、肾小管间质病变等均为慢性肾脏疾病的主要发病因素。足细胞是位于肾小球基底膜(GBM)上的高度分化的细胞,具有维持肾小球基底膜的完整性及毛细血管襻的空间结构,分泌血管内皮生长因子等功能。大量研究证实足细胞的损伤在慢性肾脏疾病如糖尿病肾病,膜性肾病(MN),IgA肾病(Ig AN)及局灶节段性肾小球硬化(FSGS)等疾病中扮演重要角色,足细胞(肾小球上皮细胞)已被认为是各种慢性肾脏疾病进展的关键细胞,也是中、西药物治疗的关键靶点。
冬虫夏草是指由冬虫夏草菌(Ophiocordyceps sinensis)侵染蝙蝠蛾科(Hepialidae)昆虫幼虫而形成的幼虫尸体与真菌子座复合体,是青藏高原特有的生物资源。近年来大量临床试验和基础研究报道了冬虫夏草通过抗炎、抗氧化及抗缺氧保护肾脏,证明了冬虫夏草对治疗各种因素造成的肾损伤具有积极的治疗作用,如IgA肾病、慢性肾小球肾炎、糖尿病肾病、慢性马兜铃肾病和药物肾毒性等。
冬虫夏草具有多种类型的代谢产物,虽然已经有大量的报道证实冬虫夏草对慢性肾脏疾病具有一定的治疗效果,但具体的活性部位或活性成分尚不明确,为了提高冬虫夏草对慢性肾脏疾病的治疗药效,开发活性成分明确、质量可控的冬虫夏草慢性肾脏疾病制剂,本发明公开了一种具有足细胞保护活性的冬虫夏草提取物的制备方法及应用。
本发明制备的冬虫夏草足细胞保护活性提取物,制备工艺简单,成本低廉,活性显著,质量易控制,对冬虫夏草治疗慢性肾脏疾病制剂的开发和利用具有重要的意义。
发明内容
本发明的目的之一在于,提供一种具有足细胞保护活性的冬虫夏草提取物,可用于慢性肾脏疾病治疗药物制剂的开发。
本发明的目的之二在于,提供上述冬虫夏草提取物的制备方法。
为实现上述目的,本发明采用如下技术方案:
一种具有足细胞保护活性的冬虫夏草提取物的制备方法,包括以下步骤:
(1)冬虫夏草新鲜药材干燥至恒重,粉碎后依次采用正己烷、乙酸乙酯和无水乙醇提取,药渣干燥备用;冬虫夏草药渣加入水提取,得到水提液W1;水提液W1脱蛋白处理后浓缩,得到浓缩液;将浓缩液分级醇沉低温放置并析出沉淀,离心得到不同乙醇浓度沉淀的醇沉物W1CC~W4CC,以及去除沉淀后的冬虫夏草水提液W2;
(2)冬虫夏草水提液W2采用大孔吸附树脂纯化,以乙醇/水混合液进行梯度洗脱,收集洗脱液,浓缩干燥,得到冬虫夏草提取物W5CC;
(3)将醇沉物W1CC与提取物W5CC按一定比例混合,得到具有足细胞保护活性的冬虫夏草提取物WS。
优选的,步骤(1)中,所述依次采用正己烷、乙酸乙酯和无水乙醇提取,所用的料液比均为1:5~10,提取次数均为3次,提取方法均为超声或回流;所述加入水提取,所用的料液比为1:5~10,提取次数为3次,提取方法为超声或回流。
优选的,步骤(1)中,所述脱蛋白处理是将冬虫夏草水提液W1与等体积的二氯甲烷-正丁醇混合溶液混合,剧烈振摇脱蛋白,重复除蛋白10次。所述的二氯甲烷-正丁醇混合溶液中二氯甲烷:正丁醇=1:1~3,体积比,优选的,二氯甲烷:正丁醇=1:1,体积比。
优选的,步骤(1)中,所述浓缩是浓缩至密度为1.0g/mL~1.1g/mL。更优选,是浓缩至密度为1.02g/mL。
优选的,步骤(1)中,所述醇沉物W1CC~W4CC的制备步骤为:在浓缩液中先加入乙醇至乙醇浓度为20%,在4℃放置12h析出沉淀,离心得沉淀W1CC后继续加入乙醇至乙醇浓度为40%,在4℃放置12h析出沉淀,离心得沉淀W2CC后继续加入乙醇至乙醇浓度为60%,在4℃放置12h析出沉淀,离心得沉淀W3CC后继续加入乙醇至乙醇浓度为80%,在4℃放置12h析出沉淀,离心得沉淀W4CC以及去除沉淀后的冬虫夏草水提液W2。
优选的,步骤(2)中,所述大孔树脂为AB-8、D-101、D301、HP-20、S-8、X-5、XAD-1、XAD-4、H-103中的一种。更优选,所述大孔树脂为AB-8、D-101、HP-20、D301中的一种。
优选的,步骤(2)中,所述梯度洗脱是以乙醇/水体积比为0:100~80:20进行洗脱;所述收集洗脱液是收集乙醇/水体积比为0:100~20:80的洗脱液。
优选的,步骤(2)中,样品的上样浓度为1.01g/mL,洗脱速率为3BV/h。
优选的,步骤(2)中,所述浓缩是指减压浓缩,温度60℃,所述干燥是指减压真空干燥、冷冻干燥或喷雾干燥。
优选的,步骤(2)中,浓缩液的终浓度为1.2g/mL,,减压真空干燥温度为60℃。
优选的,步骤(3)中,所述醇沉物W1CC与提取物W5CC是按质量比为1:1~50混合。更优选,所述醇沉物W1CC与提取物W5CC是按质量比为1:25~50混合。
优选的,步骤(2)中,所述冬虫夏草提取物W5CC的高效液相指纹图谱中包含腺苷、肌苷、鸟苷和胸腺嘧啶四种药效成分。
优选地,所述步骤(2)中,冬虫夏草提取物W5CC的高效液相指纹图谱色谱条件为:
流动相:以A相为超纯水,B相为乙腈进行梯度洗脱,所述流动相梯度条件为:0~10min,流动相中A(100%→100%),流动相B(0%→0%);10~25min,流动相中A(100%→90%),流动相B(0%→10%);25~30min,流动相中A(90%→80%),流动相B(10%→20%);30~35min,流动相中A(80%→100%),流动相B(20%→0%);35~40min,流动相中A(100%→100%),流动相B(0%→0%);
色谱柱:C18色谱柱,优选为InfinityLab Poroshell 120EC-C18,规格:4.6×100mm,2.7Micron。
流速:0.5mL/min;
柱温:30℃
检测波长:227nm。
本发明还提供一种根据上述制备方法制备得到的具有足细胞保护活性的冬虫夏草提取物。
本发明还提供上述的冬虫夏草提取物在制备保护足细胞的药物和/或保健品中的应用。
本发明还提供上述的冬虫夏草提取物在制备防治慢性肾脏疾病的药物和/或保健品中的应用。
优选的,冬虫夏草提取物WS的最终使用浓度为50-500μg/mL。
本发明还提供一种保护足细胞或防治慢性肾脏疾病的药物和/或保健品,其包含上述的冬虫夏草提取物作为活性成分。
与现有技术相比,本发明具有如下优点:
1.本发明的一种具有足细胞保护活性的冬虫夏草提取物,能够有效地降低阿霉素(Adriamycin,ADM)诱导的小鼠足细胞株MPC5损伤,提高足细胞MPC5的生长率,并以活性模型为指导,对冬虫夏草足细胞保护活性成分进行纯化、去杂质;以阿霉素刺激足细胞,可以诱导足细胞凋亡造成慢性损伤,足细胞是肾小球基底膜的最外层屏障,若足细胞造成损伤将导致肾小球过滤功能下降,从而产生蛋白尿,慢性肾脏疾病是造成足细胞损伤的主要因素,保护足细胞,降低足细胞的损伤并促进足细胞再生是治疗慢性肾脏疾病的主要途径。本发明建立在阿霉素诱导小鼠足细胞MPC5损伤的体外模型中,通过检测加入冬虫夏草提取物后阿霉素对足细胞生长的抑制率,评价冬虫夏草提取物对足细胞的保护作用。
2.本发明的一种冬虫夏草足细胞保护活性提取物属于冬虫夏草两种不同活性部位的复合物,经过两种不同活性部位的配比使用,相比单一使用时活性得到增强,进一步分析获知其中活性部位W1CC主要含大分子多糖类化合物,活性部位W5CC高效液相指纹图谱主要包含五种活性成分,并且鉴定了其中四种,对冬虫夏草提取物的质量控制提供了有效的方法。
3.本发明通过使用多种不同极性的溶剂提取,得到不同极性提取物,结合活性筛选模型,去除非活性成分,最终获得具有显著活性的冬虫夏草提取物。提取和浓缩方法高效,提取方法相对比较稳定且品质可控,为批量生产及广泛推广提供了参考。
附图说明
图1为冬虫夏草提取物W5CC的HPLC指纹图谱(峰1:肌苷;峰2:鸟苷;峰3:未知化合物;峰4:胸腺嘧啶;峰5:腺苷)。
图2为足细胞生长图片(模型组:加入阿霉素但未加样品的处理;WS组:同时加入阿霉素和冬虫夏草提取物WS样品的处理)。
具体实施方式
以下实施例是对本发明的进一步说明,而不是对本发明的限制。
实施例1
一种具有足细胞保护活性的冬虫夏草提取物的制备方法,包括以下步骤:
选取人工培育冬虫夏草50g作为原料,冷冻干燥至恒重后粉碎,过10目筛网,得到冬虫夏草粗粉,在冬虫夏草粗粉中加入500mL正己烷溶剂,超声提取,超声提取使用的功率为400W,工作频率为40KHz,提取时间为15min,提取3次,得正己烷提取物2.51g(收率5.02%),冬虫夏草药渣常温放置,挥干正己烷溶剂备用;在冬虫夏草药渣中加入500mL乙酸乙酯溶剂,超声提取,超声提取使用的功率为400W,工作频率为40KHz,提取时间为15min,提取3次,得到乙酸乙酯提取物0.75g(收率1.50%),冬虫夏草药渣常温放置,挥干乙酸乙酯溶剂备用;在冬虫夏草药渣中加入500mL无水乙醇溶剂,超声提取,超声提取使用的功率为400W,工作频率为40KHz,提取时间为15min,提取3次,得到无水乙醇提取物0.89g(收率1.79%),冬虫夏草药渣常温放置,挥干无水乙醇溶剂备用;在冬虫夏草药渣中加入500mL水,加热回流提取,提取时间为30min,提取3次,收集冬虫夏草水提液W1。在冬虫夏草水提液W1中加入等体积的二氯甲烷-正丁醇(1:1,体积比)混合溶剂,剧烈振摇析出蛋白后静置沉淀,离心除去沉淀,如此重复除蛋白10次,除蛋白后的冬虫夏草提取液W1在60℃下减压浓缩至密度为1.02g/mL,在W1的浓缩液中加入乙醇至含醇量为20%,放入4℃冰箱12h,离心得20%醇沉物0.41g(W1CC,收率0.82%),继续加入乙醇至含醇量为40%,放入4℃冰箱12h,离心得40%醇沉物0.39g(W2CC,收率0.78%),继续加入乙醇至含醇量为60%,放入4℃冰箱12h,离心得60%醇沉物0.72g(W3CC,收率1.44%),继续加入乙醇至含醇量为80%,放入4℃冰箱12h,离心得到80%醇沉物1.18g(W4CC,收率2.36%)以及去除沉淀后的冬虫夏草水提液W2。
冬虫夏草水提液W2浓缩至无醇味后调节密度至1.01g/mL,加入到100g AB-8大孔树脂柱中,以3BV/h的流速洗脱,梯度洗脱,洗脱剂依次为水、20%乙醇/水、40%乙醇/水、60%乙醇/水和80%乙醇/水,每种洗脱剂采用3个柱体积的溶剂洗脱,收集水-20%乙醇/水的洗脱液,60℃减压浓缩至1.2g/mL,60℃减压真空干燥至恒重,得冬虫夏草提取物W5CC,收率为11.8%。高效液相色谱测定冬虫夏草提取物W5CC的指纹图谱,检测波长为227nm,柱温为30℃,流速为0.5mL/min,色谱柱优选为InfinityLab Poroshell 120EC-C18,规格:4.6×100mm,2.7Micron,流动相梯度程序为:以A相为超纯水,B相为乙腈,0~10min,流动相中A(100%→100%),流动相B(0%→0%);10~25min,流动相中A(100%→90%),流动相B(0%→10%);25~30min,流动相中A(90%→80%),流动相B(10%→20%);30~35min,流动相中A(80%→100%),流动相B(20%→0%);35~40min,流动相中A(100%→100%),流动相B(0%→0%),指纹图谱中含腺苷、肌苷、鸟苷和胸腺嘧啶四种药效成分(图1)。将20%醇沉物W1CC和提取物W5CC按照质量比1:50混合均匀,得到两个活性部位的复合物WS。
实施例2
冬虫夏草提取物足细胞保护活性检测:
1.试剂与仪器
小鼠足细胞株MPC5;盐酸阿霉素(ADM);DMEM高糖培养基;胎牛血清(FBS);磷酸盐缓冲液(PBS);二甲基亚砜(DMSO);1%P/S双抗;Cell counting kit 8(cck8);精密电子天平;生物安全柜;二氧化碳培养箱;倒置显微镜;低速冷冻离心机;酶标仪;数显恒温水浴锅。
2.MPC5细胞的培养
基础培养基为DMEM培养液+10%FBS+1%P/S双抗;培养条件为37℃、5%CO2及饱和湿度;培养2~3天细胞密度达到90%后可用于实验。
3.冬虫夏草提取物对细胞生长率的影响
将状态良好的足细胞调整密度为5×103个/mL,将其接种至96孔板内(每组6个复孔,每孔100μL),置37℃,5%CO2培养箱中培养24h。将原培养基弃去,设置正常组、模型组和样品组,正常组的培养基不加盐酸阿霉素和样品,模型组在培养基中加入盐酸阿霉素溶液(终浓度0.2μg/mL),样品组在培养基中加入盐酸阿霉素(终浓度0.2μg/mL)和冬虫夏草提取物(终浓度见表1),培养基加入量为100μL,每组设置6个复孔,培养24h后,每孔加入cck8试剂10μL,37℃孵育2h,酶标仪检测每孔的吸光度值,根据公式计算抑制率。
细胞抑制率=1-(加药孔-本底值)/(对照孔-本底值)×100%
实验数据采用SPSS22.0统计软件进行单因素方差分析进行显著性差异分析,p<0.05表示显著差异,具有统计学意义。
4.数据分析
不同处理对小鼠足细胞MPC5生长的影响见图2和表1。
由表1可知,小鼠足细胞MPC5在阿霉素的作用下生长率明显下降,与正常组细胞生长率相比具有显著性差异,说明细胞模型造模成功。20%醇沉物(W1CC)和冬虫夏草提取物W5CC在500μg/mL浓度下均表现出一定的足细胞保护活性,40%醇沉物(W2CC)、60%醇沉物(W3CC)、80%醇沉物(W4CC)在3个浓度下未检测出足细胞保护活性,20%醇沉物(W1CC)和冬虫夏草提取物W5CC的复合物WS对阿霉素诱导损伤的足细胞表现出显著的促进生长活性,在一定程度上降低了阿霉素对足细胞的损伤作用,经过本发明技术得到的冬虫夏草提取物WS在对足细胞的保护活性表现得更加强,且呈现出量效关系。
表1冬虫夏草提取物对阿霉素诱导损伤的足细胞生长率影响
注:*代表与模型组相比较,有显著性差异(p<0.05);
**代表与模型组相比较,有明显的显著性差异(p<0.01)。
本发明的一种冬虫夏草足细胞保护活性提取物,能够有效地抑制阿霉素对足细胞造成的损伤,有效提高阿霉素损伤足细胞的生长率,表现出显著的足细胞保护活性,并以活性模型为指导,对冬虫夏草足细胞保护活性物质进行纯化、去杂质。以阿霉素刺激足细胞,对足细胞产生慢性损伤,可模拟多种慢性肾脏疾病如糖尿病肾病,膜性肾病(MN),IgA肾病(Ig AN)及局灶节段性肾小球硬化(FSGS)等疾病对肾脏足细胞造成的损伤,足细胞已被认为是各种慢性肾脏疾病进展的关键细胞。本发明建立在阿霉素诱导足细胞MPC5产生慢性损伤的体外模型中,通过检测冬虫夏草提取物对阿霉素刺激后足细胞生长率的影响,评价冬虫夏草提取物对足细胞的保护活性。本发明的一种冬虫夏草足细胞保护活性提取物的制备方法,通过提纯、分离和浓缩等步骤,结合活性部位配比成复合物得到具有显著保护足细胞活性的提取物,对冬虫夏草治疗各种慢性肾脏疾病的药效基础进一步进行了诠释,提取和浓缩方法高效,且提取物相对比较稳定且品质可控。
以上仅是本发明的优选实施方式,应当指出的是,上述优选实施方式不应视为对本发明的限制,本发明的保护范围应当以权利要求所限定的范围为准。对于本技术领域的普通技术人员来说,在不脱离本发明的精神和范围内,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (10)
1.一种具有足细胞保护活性的冬虫夏草提取物的制备方法,其特征在于,包括以下步骤:
(1)冬虫夏草新鲜药材干燥至恒重,粉碎后依次采用正己烷、乙酸乙酯和无水乙醇提取,药渣干燥备用;冬虫夏草药渣加入水提取,得到水提液W1;水提液W1脱蛋白处理后浓缩,得到浓缩液;将浓缩液分级醇沉低温放置并析出沉淀,离心得到不同乙醇浓度沉淀的醇沉物W1CC~W4CC,以及去除沉淀后的冬虫夏草水提液W2;
(2)冬虫夏草水提液W2采用大孔吸附树脂纯化,以乙醇/水混合液进行梯度洗脱,收集洗脱液,浓缩干燥,得到冬虫夏草提取物W5CC;
(3)将醇沉物W1CC与提取物W5CC按一定比例混合,得到具有足细胞保护活性的冬虫夏草提取物WS。
2.根据权利要求1所述的制备方法,其特征在于,步骤(1)中,所述依次采用正己烷、乙酸乙酯和无水乙醇提取,所用的料液比均为1:5~10,提取方法均为超声或回流;所述加入水提取,所用的料液比为1:5~10,提取方法为超声或回流。
3.根据权利要求1所述的制备方法,其特征在于,步骤(1)中,所述浓缩是浓缩至密度为1.0g/mL~1.1g/mL。
4.根据权利要求1所述的制备方法,其特征在于,步骤(1)中,所述醇沉物W1CC~W4CC的制备步骤为:在浓缩液中先加入乙醇至乙醇浓度为20%,在4℃放置12h析出沉淀,离心得沉淀W1CC后继续加入乙醇至乙醇浓度为40%,在4℃放置12h析出沉淀,离心得沉淀W2CC后继续加入乙醇至乙醇浓度为60%,在4℃放置12h析出沉淀,离心得沉淀W3CC后继续加入乙醇至乙醇浓度为80%,在4℃放置12h析出沉淀,离心得沉淀W4CC以及去除沉淀后的冬虫夏草水提液W2。
5.根据权利要求1所述的制备方法,其特征在于,步骤(2)中,所述梯度洗脱是以乙醇/水体积比为0:100~80:20进行洗脱;所述收集洗脱液是收集乙醇/水体积比为0:100~20:80的洗脱液。
6.根据权利要求1所述的制备方法,其特征在于,步骤(3)中,所述醇沉物W1CC与提取物W5CC是按质量比为1:1~50混合。
7.根据权利要求1-6任一项所述的制备方法制备得到的具有足细胞保护活性的冬虫夏草提取物。
8.权利要求7所述的冬虫夏草提取物在制备保护足细胞的药物和/或保健品中的应用。
9.权利要求7所述的冬虫夏草提取物在制备防治慢性肾脏疾病的药物和/或保健品中的应用。
10.一种保护足细胞或防治慢性肾脏疾病的药物和/或保健品,其特征在于,包含权利要求7所述的冬虫夏草提取物作为活性成分。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311356381.2A CN117323352A (zh) | 2023-10-19 | 2023-10-19 | 一种具有足细胞保护活性的冬虫夏草提取物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311356381.2A CN117323352A (zh) | 2023-10-19 | 2023-10-19 | 一种具有足细胞保护活性的冬虫夏草提取物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117323352A true CN117323352A (zh) | 2024-01-02 |
Family
ID=89295213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311356381.2A Pending CN117323352A (zh) | 2023-10-19 | 2023-10-19 | 一种具有足细胞保护活性的冬虫夏草提取物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117323352A (zh) |
-
2023
- 2023-10-19 CN CN202311356381.2A patent/CN117323352A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107335049B (zh) | 菊科类型环肽化合物作为cGAS-STING信号通路抑制剂的应用 | |
WO2019205662A1 (zh) | 一种蛹虫草培养基多糖及其分离纯化方法和用途 | |
KR100988877B1 (ko) | 작약 추출물을 유효성분으로 하는 b형 간염 치료제 조성물 | |
CN102423346B (zh) | 一种牡丹皮提取物及其制备方法和用途 | |
CN109806285B (zh) | 一种具有降尿酸活性的辣木叶提取物及其制备方法与应用 | |
CN112168951A (zh) | 茜草环肽化合物在制药中的应用 | |
CN117323352A (zh) | 一种具有足细胞保护活性的冬虫夏草提取物及其制备方法和应用 | |
JP2004091780A (ja) | Antrodiacamphorata菌体の多糖類 | |
CN101948439B (zh) | 鹿茸活性生物碱类化合物的提取方法及在医药上的应用 | |
CN1141101C (zh) | 治疗乙肝的药物及其制备方法 | |
CN1793165A (zh) | 一种芦笋皂甙的生产方法 | |
TWI618540B (zh) | Composition for preventing renal toxicity caused by drug toxicity, preparation method thereof and Its use | |
CN108822175B (zh) | 3,16-雄甾烯二酮类化合物及其应用 | |
CN109810160B (zh) | 冷杉三萜类化合物、其制备方法及其抗肝炎病毒的应用 | |
CN109248202A (zh) | 一种花楸果及其提取物在制备抗病毒性肝炎药物中的应用 | |
CN104288220A (zh) | 一种富含肌醇和芦丁的槐米提取物及其制备方法 | |
CN113018281B (zh) | 一种Pellino1天然小分子抑制剂及其应用 | |
CN111812252B (zh) | 一种对植物中降糖功能化合物的筛选及分离方法 | |
CN112321479B (zh) | 一种桑寄生中具有抑菌活性的吲哚-4-甲醛化合物、制备方法及其应用 | |
CN114075198B (zh) | 一种新型黄芪生物碱及其在治疗神经退行性疾病中的应用 | |
CN108558975B (zh) | 12β-羟基-雄甾4,14-二烯-16-酮类化合物及其应用 | |
CN100335096C (zh) | 一种抗炎症性变态反应的中药组合物及其制备方法 | |
CN115919925A (zh) | 苦参及其水提物在治疗抗肺炎链球菌肺炎中的应用 | |
CN115710302A (zh) | 一种具有抗ev71病毒功能的灰树花低分子量多糖肽及其制备方法 | |
JP3286554B2 (ja) | 消化管吸収促進剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |